Alan Pollack, MD, PhD, presented “Evaluation and Management of Localized and Recurrent Prostate Cancer: Genetic Cancer Profiling ” during the Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer in fall 2020.
How to cite: Pollack, Alan. “Evaluation and Management of Localized and Recurrent Prostate Cancer: Genetic Cancer Profiling.” October 2020. Accessed Nov 2024. https://dev.grandroundsinurology.com/evaluation-and-management-of-localized-and-recurrent-prostate-cancer-genetic-cancer-profiling/
Evaluation and Management of Localized and Recurrent Prostate Cancer: Genetic Cancer Profiling – Summary
Alan Pollack, MD, PhD, Professor and Chair in the Department of Radiation Oncology at University of Miami Health, looks at genetic cancer profiling for prostate cancer risk assessment and its implications for treatment. He begins with a discussion of the development of a habitat risk scoring system for prostate cancer which, via quantitative pixel by pixel assessment, can generate high-risk volumes for targeting. Dr. Pollack then moves on to transcriptome analysis using genomic classifiers like Decipher, noting that these classifiers have a relationship with Gleason score, though it is not absolute, and can predict 10-year distant metastasis. He also considers how to understand genomic risk of habitats from quantitative MRI, observing the significant connections between radiogenomic features and transcriptomic features. Dr. Pollack concludes with a discussion of how genomic signatures might influence critical management, going through how Decipher scores could change risk stratification and highlighting several trials looking at habitat targeted radiotherapy.
The Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer brings together key international opinion leaders of every clinical subspecialty involved in patient care. This event is an integral part of the AdMeTech Foundation’s Annual Summit, which was established in 2016 and became seminal in shaping the state of the art and future vision for precision care. The goal of this event is three-fold: 1) Educating the key stakeholders; 2) Supporting a sustained cross-disciplinary dialogue and consensus on the best emerging clinical practices and research priorities; and 3) Expediting clinical adoption of promising novel diagnostics and therapeutics. For more educational activities from this virtual event, visit our collection page.
ABOUT THE AUTHOR
Alan Pollack, MD, PhD, is Professor and Chair in the Department of Radiation Oncology at the University of Miami Miller School of Medicine in Miami, Florida. He also serves as Interim Deputy Director of the Sylvester Comprehensive Cancer Center, part of the University of Miami Health System. Dr. Pollack received both his MD and his PhD from the University of Miami. His research interests center on the therapeutic management of prostate cancer, with an emphasis on applying biomarkers, including quantitative imaging, tissue, genomic, and liquid biopsy markers, to predict risk. Dr. Pollack’s other research interests include active surveillance, radiotherapy, androgen deprivation therapy, radiation dose escalation, and radiation fractionation. He also co-leads the NCI consortium on imaging and biomarkers and the genitourinary translational research program in the NRG cooperative group. A key emphasis of ongoing trials and Dr. Pollack’s laboratory is the integration of quantitative multiparametric MRI to better risk classify habitats in the prostate, assess tumor heterogeneity, direct prostate biopsies, and target radiotherapy delivery.
